Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--May 29, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
馬薩諸塞州列剋星敦市--(美通社)--2024年5月29日--Aldeyra Therapeutics股份有限公司（納斯達克：ALDX）（Aldeyra）是一家處於臨床階段的生物技術公司，致力於開發治療免疫介導和代謝性疾病的創新療法，今天宣佈，公司總裁兼首席執行官Todd C. Brady博士將在Jefferies Global Healthcare Conference上參加嘉賓演講。
Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 3:30 p.m. ET Wednesday, June 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.
Brady博士將與Jefferies生物技術股票研究高級副總裁Kelly Shi博士於2024年6月5日週三下午3:30開始對話。若需觀看現場網絡直播，請登錄Aldeyra網站的投資者與媒體板塊:https://ir.aldeyra.com完成嘉賓演講後，網絡直播將保留90天。
About Aldeyra
關於Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
Aldeyra Therapeutics是一家專注於發現旨在治療免疫介導和代謝性疾病的創新療法的生物技術公司。我們的方法是開發調節蛋白質系統的藥品，而不是直接抑制或激活單個蛋白靶標，以期在最小化毒性的同時優化多條途徑。我們的產品候選包括RASP（活性醛類物質）調節劑ADX-629、ADX-246、ADX-248和與之化學相關的分子，用於潛在治療免疫介導和代謝性疾病。我們的後期產品候選包括reproxalap，一種RASP調節劑，可潛在治療乾眼病和過敏性結膜炎，以及ADX-2191，一種新型眼內注射甲氨蝶呤製劑，可潛在治療視網膜色素變性症。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
Investor & Media Contact:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投資者及媒體聯繫方式：
David Burke
電話：(917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
來源：Aldeyra Therapeutics股份有限公司
譯文內容由第三人軟體翻譯。